Events
|
Press Releases
|
Tuberculosis
T-SPOT®.
TB
Economic Impact
Guidelines
The Learning Zone
Healthcare FAQs
About Tuberculosis
Active TB Disease and Latent TB Infection
Diagnosing Tuberculosis
Why Choose T-SPOT®.
TB
TB Vaccination & Treatment
Patient Groups
Patient FAQs
Media Requests
The World Health Organization (WHO) estimates that more than one third of the world’s population is infected with Mycobacterium tuberculosis.
Press Releases
Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell
Xtend
®
reagent
Independent study demonstrates that T-SPOT
®
.
TB
assay outperforms TST in predicting TB disease
The T-SPOT
®
.
TB
Test Now Included in New CDC Guidelines
Independent peer-reviewed study demonstrates that TB contact tracing based on use of the T-SPOT
®
.
TB
assay is more cost effective
Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners
New study confirms 98.9% specificity of the T-SPOT
®
.
TB
assay
Oxford Immunotec announces contract with Scancell Ltd to measure T cell response in Phase I/II clinical immunotherapy trial
2010 World TB Day
Oxford Immunotec Strengthens Leadership Team
T-SPOT.TB is first IGRA to be Approved for Sale in Taiwan
2009 World TB Day
Oxford Immunotec announces European approval and launch of T Cell Xtend™
Oxford Immunotec Announces Board Changes
T-SPOT
®
.
TB
Gains FDA Premarket Approval
Study Results Confirm T-SPOT
®
.
TB
Performance is Not Affected by Low CD4 Count in HIV Infected Subjects
42 Articles
1 - 15
Next
Get Email Updates